George Ka Kit Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HKU), FRCP (Edin, Lond), FAASLD (USA)

George Ka Kit Lau is currently the Chairman of Humanity and Health Medical Center, Hong Kong SAR and Chair Professor and Director of 302 Beijing - Humanity and Health hepatitis C clinic , Beijing. He has a distinguished career in the conduct of translational research in the field of chronic HBV and HCV infection. He has pioneered work in adoptive clearance of HBV infection and the use of pre-emptive lamivudine to prevent HBV reactivation after chemotherapy. In the forefront of biological therapy for chronic hepatitis B infection, he provided the first evidence in humans that transfer of hepatitis B core antigen-reactive T cells is associated with resolution of chronic HBV infection.

Recently his group has demonstrated the the feasibility of ultrashort duration of therapy (3 weeks) in Chinese GT1b non cirrhotic using response guided approach with SOLDAPI regimen and has reported the risk of HBV reactivation in CHC patients treated with DAAs in HBV endemic area. Professor Lau has more than 500 publications in scientific journals, such as the New England Journal of Medicine, Lancet, Gastroenterology, Journal of Hepatology, Hepatology and Blood, with citations of over 10,000.

Recently his group has demonstrated the the feasibility of ultrashort duration of therapy (3 weeks) in Chinese GT1b non cirrhotic using response guided approach with SOLDAPI regimen and has reported the risk of HBV reactivation in CHC patients treated with DAAs in HBV endemic area. Professor Lau has more than 500 publications in scientific journals, such as the New England Journal of Medicine, Lancet, Gastroenterology, Journal of Hepatology, Hepatology and Blood, with citations of over 10,000.